- Home
- RVPH vs DRIO Comparison
RVPH vs DRIO Comparison
Compare RVPH & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- DRIO
- Stock Information
- Founded
- RVPH 2006
- DRIO 2011
- Country
- RVPH United States
- DRIO United States
- Employees
- RVPH N/A
- DRIO N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- DRIO Medical/Dental Instruments
- Sector
- RVPH Health Care
- DRIO Health Care
- Exchange
- RVPH Nasdaq
- DRIO Nasdaq
- Market Cap
- RVPH 32.8M
- DRIO 30.5M
- IPO Year
- RVPH N/A
- DRIO N/A
- Fundamental
- Price
- RVPH $0.39
- DRIO $0.69
- Analyst Decision
- RVPH Strong Buy
- DRIO Strong Buy
- Analyst Count
- RVPH 5
- DRIO 2
- Target Price
- RVPH $9.00
- DRIO $2.50
- AVG Volume (30 Days)
- RVPH 3.5M
- DRIO 124.6K
- Earning Date
- RVPH 08-13-2025
- DRIO 08-07-2025
- Dividend Yield
- RVPH N/A
- DRIO N/A
- EPS Growth
- RVPH N/A
- DRIO N/A
- EPS
- RVPH N/A
- DRIO N/A
- Revenue
- RVPH N/A
- DRIO $28,034,000.00
- Revenue This Year
- RVPH N/A
- DRIO $13.66
- Revenue Next Year
- RVPH N/A
- DRIO $24.50
- P/E Ratio
- RVPH N/A
- DRIO N/A
- Revenue Growth
- RVPH N/A
- DRIO 47.20
- 52 Week Low
- RVPH $0.30
- DRIO $0.50
- 52 Week High
- RVPH $4.28
- DRIO $1.55
- Technical
- Relative Strength Index (RSI)
- RVPH 36.56
- DRIO 49.61
- Support Level
- RVPH $0.38
- DRIO $0.67
- Resistance Level
- RVPH $0.45
- DRIO $0.74
- Average True Range (ATR)
- RVPH 0.05
- DRIO 0.03
- MACD
- RVPH 0.01
- DRIO 0.00
- Stochastic Oscillator
- RVPH 21.69
- DRIO 43.71
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.